Key Findings from the ACROINNOVA 2 Study: Octreotide SC Depot (CAM2029) Promising Treatment for Acromegaly Patients
![LivaRava Technology Default](https://store.livarava.com/c50dd4fc-29b9-11ef-ab78-0d95d4a28fb2.png)
ACROINNOVA 2 Study Recap
The ACROINNOVA 2 study conducted by Camurus focuses on the efficacy of octreotide SC depot (CAM2029) in treating acromegaly patients. The results showcase a notable increase in biochemical response rates compared to standard-of-care at baseline.
Improved Symptom Management
Patients receiving octreotide SC depot (CAM2029) experienced continuous enhancement in managing acromegaly symptoms, indicating a positive impact on their quality of life.
Conclusion: Camurus' ACROINNOVA 2 study demonstrates promising results in the treatment of acromegaly, offering improved symptom management and a favorable safety profile.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.